title: Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action.
abstract: Combined potassium and calcium channel blocking activities are suggested to be the basis for antiarrhythmic efficacy with low proarrhythmic risk. The electrophysiologic effects of SB-237376 were investigated in single myocytes and arterially perfused wedge preparations of canine or rabbit left ventricles. The concentration-dependent prolongation of action potential duration (APD) and QT interval by SB-237376 was bell-shaped and the maximum response occurred at 1-3 microM SB-237376 inhibited rapidly activating delayed rectifier K current (I(Kr) ) with an IC50 of 0.42 microM and use-dependently blocked L-type Ca current (I (Ca,L) ) at high concentrations. The SB-237376 (3 microM) induced phase-2 early afterdepolarizations (EADs) in five of six rabbit wedge preparations but none of six canine wedge preparations. This is probably due to larger increases of APD, QT interval, and transmural dispersion of repolarization (TDR) in rabbits than dogs. Based on the drug effects on QT interval, TDR, and EAD in rabbit ventricular wedge preparations, a scoring system predicted lower proarrhythmic risk for SB-237376 than for dl-sotalol, a specific I blocker. In conclusion, SB-237376 increases APD, QT interval, and TDR mainly by I (Kr) inhibition. These effects are self-limited due to SB-237376-induced I(Ca,L) blockade at high concentrations, which may explain its lower proarrhythmic risk than dl-sotalol.
authors.affiliation: Main Line Health Heart Center, Wynnewood, Pennsylvania 19096, USA.
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Xu
authors.forename: Gan-Xin
authors.initials: GX
authors.lastname: Yan
authors.forename: Ying
authors.initials: Y
authors.lastname: Wu
authors.forename: Tengxian
authors.initials: T
authors.lastname: Liu
authors.forename: Peter R
authors.initials: PR
authors.lastname: Kowey
mesh_terms: D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001549:Benzamides / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D015220:Calcium Channels / Q000502:physiology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D015507:Drugs, Investigational / Q000494:pharmacology; D022062:Electrophysiologic Techniques, Cardiac / Q000379:methods*; D005260:Female; D008297:Male; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000502:physiology; D026902:Potassium Channel Blockers / Q000494:pharmacology*; D015221:Potassium Channels / Q000502:physiology
chemical_list: C477807:(N-(3-((2-(3,4-dimethoxyphenyl)ethyl)ethyl)amino)propyl) -4-nitrobenzamide hydrochloride; D000889:Anti-Arrhythmia Agents; D001549:Benzamides; D002121:Calcium Channel Blockers; D015220:Calcium Channels; D015507:Drugs, Investigational; D026902:Potassium Channel Blockers; D015221:Potassium Channels